Oral medicine for treating stroke

Abstract

The invention relates to an oral medicine for treating stroke. The oral medicine is prepared from the following traditional Chinese medicine raw materials in parts by mass: 12-40 parts of astragalus membranaceus, 12-40 parts of kudzu vine root, 10-25 parts of red paeony root, 10-25 parts of ligusticum wallichii, 10-20 parts of peach kernel, 10-25 parts of pepper kernel oil, 10-25 parts of lycopodium clavatum, 10-25 parts of ginkgo biloba extract, 6-20 parts of angelica sinensis and 3-10 parts of gastrodia elata. The oral medicine has the effects of reducing blood viscosity, prolonging blood coagulation time and inhibiting thrombus formation, and has an average effective rate of 92.87% and a remarkable treatment effect after being clinically used. The oral medicine for treating stroke has the effects of tonifying qi and activating blood, and dispersing blood stasis and dredging collaterals, and is suitable for patients with qi deficiency and blood stasis syndromes such as hemiplegia, facial paralysis, hemianesthesia, limb spasm and unsmooth speech caused by the stroke recovery period.

Description

Technical field [0001] The present invention belongs to the technical field of medical formulation containing a raw material or its reaction product of unknown structure, and a material derived from a plant. Background technique [0002] Stroke, but also known as stroke, cerebrovascular accidents, usually refers to a group of acute diseases including cerebral hemorrhage, cerebral infarction, spider mesencing bleeding, specific definition is an acute attack, rapid limitation or diffuse brain The cerebrovascular clinical event of the functional deletion is a common disease in middle-aged and elderly people. It is one of the three major diseases in today's human mortality. It is also the fastest development in three major diseases, the slowest recovery, the most dead. The maximum of disabled disease is greatly caused to human beings, bringing serious harm to families and society. Moreover, as people's dietary structure changes, the rhythm of life is accelerating, and the incidence o...

AI Technical Summary

Problems solved by technology

[0003] The currently marketed drugs for the treatment of stroke can be specifically divided into two categories. One is local standard old drugs that have been marketed in the early stage, such as Huatuo Zaizao Pills, Zhongfenghuichun Pills, etc. These products have not undergone strict randomization, double-blind, Controlled, multi-center clinical trials, the curative effect needs to be further confirmed, and the indications are extensive, and the curative effect is not concentrated; the Chinese patent medicines approved in recent years, such as Nao'an Capsules, Naoxintong Capsules, etc., have relatively definite curative effects, but they are all Large and comprehensive products, the curative effect is not outstanding, and the pertinence is not strong

Images